By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Neuraminidase inhibitors > Tamiflu > Tamiflu Pregnancy and Breastfeeding Warnings
Neuraminidase inhibitors

Oseltamivir Pregnancy and Breastfeeding Warnings

Contents
Tamiflu Pregnancy Warnings Tamiflu Breastfeeding Warnings

Tamiflu Pregnancy Warnings

Animal studies have failed to reveal evidence of teratogenicity; animal data (with doses 2 to 100 times the maximum recommended human dose) have revealed that the drug crosses the placenta. There are no controlled data in human pregnancy; data from postmarketing reports and observational studies (over 1000 exposed outcomes during the first trimester) showed no malformative nor fetal/neonatal toxicity by this drug.

Published prospective and retrospective observational studies of about 1500 women exposed to this drug during pregnancy (including about 400 exposed in the first trimester) indicate no increase in the observed rate of congenital malformations above the general comparison population, regardless of when exposure occurred during the gestation period. However, when each study was evaluated separately, all had inadequate sample sizes and some lacked dosing information, preventing definitive assessment of risk.

Pregnant women have higher risk of severe complications from influenza, which may lead to adverse pregnancy and/or fetal outcomes.

AU TGA pregnancy category B1: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have not shown evidence of an increased occurrence of fetal damage.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.

AU TGA pregnancy category: B1
US FDA pregnancy category: C

Comments:
-Maternal and embryo/fetal risk due to the mother's underlying condition, available safety data, and pathogenicity of circulating influenza virus strain should be considered.
-According to the US CDC, this drug is preferred for treatment of pregnant women with suspected/confirmed influenza.

See references

Tamiflu Breastfeeding Warnings

Caution is recommended; benefit should outweigh risk.

Excreted into human milk: Yes (parent drug and active metabolite in low levels)

Comments:
-Low levels in milk are not expected to cause harmful effects in the nursing infant.
-Low levels in milk resulting in a subtherapeutic dose to the infant, pathogenicity of circulating influenza virus strain, and underlying maternal condition should also be considered.

Based on limited data, parent drug (oseltamivir) and its active metabolite (oseltamivir carboxylate) are poorly excreted into breast milk. Maternal doses of 150 mg/day produced low levels in milk.

At 0, 0.5, 1, 2, 4, 8, 12, and 24 hours after a single 75 mg oral dose, milk samples were donated by 7 postpartum women bottle feeding their infants. Parent drug and active metabolite were measured in milk samples. The peak milk levels of parent drug and active metabolite averaged 26.9 mcg/L about 3.4 hours after the dose and 41.9 mcg/L about 18.9 hours after the dose, respectively. Based on AUC data reported in the paper and standardized milk intake of 150 mL/kg/day, a fully breastfed infant would receive about 0.9 mcg/kg/day of parent drug and 3.6 mcg/kg/day of active metabolite. The usual maternal dose (75 mg twice a day) would double these values, but the total is much less than doses reportedly used in infants (1 to 7 mg/kg/day).

A woman who was breastfeeding her 9-month-old infant received 75 mg orally twice a day for 5 days after accidentally sticking herself with a needle contaminated with 2009 H1N1 influenza virus. Breastfeeding was stopped during this time due to possible side effects in the infant. Eleven milk samples were collected twice daily over the 5-day period by completely emptying both breasts. The sample timing varied, with 8 of the samples collected 30 minutes before or after a dose. The steady-state concentration of the active metabolite was reached after 3 days and averaged 37 to 39 ng/mL. The maximum relative infant dose (parent drug plus active metabolite) was estimated to be 0.012 mg/kg/day, or about 0.5% of the mother's weight-adjusted dose (assuming 60 kg body weight). Based on this study, the drug level in breast milk appears to be clinically insignificant. Also, the potential dose for a nursing infant is much less than the pediatric dose.

The US CDC recommended women infected with 2009 H1N1 influenza virus breastfeed, regardless of whether they were being treated, due to the advantages of breast milk for the infant's immune system.

See references

Share this Article
Latest News
Medical News

Aging and longevity: What role might coffee play?

Jun 02, 2025
Seed oils: Omega-6 fatty acids may lower diabetes, heart disease risk
Type 2 diabetes: Sugary drinks may significantly raise risk
COVID-19: Who do the new vaccine guideline changes affect?
Vitamin D supplements may help slow down aging by 3 years
Aging: Exercise timing, consistency can affect heart and lung fitness
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by